sözaltı news Science
Science
EN AZ

Circulating microRNAs and depressive symptom severity in older adults: evidence for an association with miR-29b-3p

nature.com 18.09.2026 02:00 1 views

Depressive symptoms in later life represent a major clinical concern because they are associated with cognitive decline, multimorbidity, and increased mortality among older adults. Although circulating microRNAs (miRNAs) emerged as potential biomarkers in major depressive disorder, their role in late-life depressive symptom severity remains poorly defined. In this study we investigated the association between plasma levels of three miRNAs involved in neuroinflammation and synaptic function (miR-23a-3p, miR-26a-5p, and miR-29b-3p) and depressive severity in a population of 123 community-dwelling subjects.

Individuals aged 65–97 years were classified for depressive status according to the 15-item Geriatric Depression Scale (GDS-15), in addition to their cognitive function, functional and nutritional status, and multimorbidity. Analysis of covariance, adjusted for demographic, cognitive and clinical covariates, found that plasma levels of all three miRNAs progressively decreased with increasing depressive symptom severity and differed significantly across GDS-15 symptom severity categories, particularly between participants with moderate and higher depressive symptom burden. Among the investigated miRNAs, miR-29b-3p showed the strongest and most robust association, remaining significant after extensive covariate adjustment and false discovery rate correction.

Analyses of predictive performance, evaluated by receiver operating characteristic (ROC) curve analysis, supported this association, showing that the inclusion of miR-29b-3p improved the discrimination of participants with more severe depressive symptoms within the study sample. Furthermore, higher miR-29b-3p levels were associated with better cognitive performance. MiR-23a-3p and miR-26a-5p were attenuated after adjustment and appeared to reflect broader aspects of aging and multimorbidity rather than depression-specific mechanisms.

Pathway enrichment analysis of predicted miR-29b-3p targets identified pathways involved in cellular stress responses and metabolic regulation, including PI3K–Akt and FOXO signaling. In conclusion, miR-29b-3p emerged as a candidate circulating marker associated with depressive symptom severity and cognitive vulnerability in older adults. The work has been made possible by the collaboration with Gruppo Baffa (Sadel Spa, Sadel San Teodoro srl, Sadel CS srl, Casa di Cura Madonna dello Scoglio, AGI srl, Casa di Cura Villa del Rosario srl, Savelli Hospital srl) in the frame of the agreement TECNOLOGIE AVANZATE PER IL MIGLIORAMENTO DEI SERVIZI ALLA PERSONA.

This research was co-funded by Italian Ministry of Health (Ministero della Salute) through the program POS Trajectory line 3.1 project FaPerME (Number: T3-AN-15 received by GP) and by Italian Ministry of University and Research (Ministero della Università e Ricerca) through the project PRIN 2022 “EXTREMAL: EXTREMe phenotypes for Aging and Longevity” [D.D.104 2.02.2022; cod. 20227KNBEJ, PNRR M4.C2.1.1] to SD. Giuseppina Rose and Serena Dato contributed equally to this work: Giuseppina Rose and Serena Dato. DiBEST (Department of Biology, Ecology and Earth Sciences), University of Calabria, Ponte Pietro Bucci cubo 4c, Rende, 87036, CS, Italy Rossella La Grotta, Paolina Crocco, Giuseppe Passarino, Giuseppina Rose & Serena Dato The authors declare no competing interests.

The study conforms to the Declaration of Helsinki regarding research involving human subjects and the protocol was approved by the local Ethical Committee (Comitato Etico Regione Calabria-Sezione Area Nord) on 2017-10-31 (code n. 25/2017). Each subject signed an informed consent for the permission to collect blood samples and usage of register-based information for research purposes. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extract — continue reading at the source.

Read full story